Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
May 28, 2022 at 14:00 PM EDT
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and milestone payments, plus tiered royalties.
